ArticleJournal of cardiovascular translational research2026
FOSL2 Regulates PANoptosis in Cardiomyocytes and Heart Failure Progression After Acute Myocardial Infarction by Promoting NLRP12.
Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NLRP12 can induce PANoptosis, a novel form of inflammatory cell death. The research aimed to investigate the mechanisms of NLRP12 in regulating PANoptosis during postinfarction heart failure (HF). C57BL/6J mice were treated with AAV-shNLRP12 before acute myocardial infarction (AMI) modeling using coronary artery ligation, and mouse cardiomyocytes were treated with lentiviruses before hypoxia. NLRP12 and FOSL2 were upregulated in myocardial tissues of AMI-induced mice and hypoxia-exposed mouse cardiomyocytes. FOSL2 activated NLRP12 in mouse cardiomyocytes by binding to its promoter. Knockdown of FOSL2 or NLRP12 improved survival and inhibited HF after AMI, including recovery of cardiac function, reduction of fibrotic area of myocardial tissues, decrease of myocardial injury, and inhibition of PANoptosis in mice. Combined overexpression of NLRP12 impaired the inhibitory effect of the knockdown of FOSL2 on HF after AMI. Our findings demonstrate that FOSL2 promotes cardiomyocyte PANoptosis by inducing the transcription of NLRP12, thereby triggering HF after AMI.
Indexed as
Identifiers
42518001What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.